Skip to main content
Supplement ScienceSupplementScience

Caralluma Fimbriata Side Effects & Safety

Evidence:Preliminary
·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

Safety Profile

Overall safety rating: Generally Safe

Potential Side Effects

  • Mild GI discomfort (constipation, stomach pain) in some users
  • Generally well tolerated in short-term trials

Drug & Supplement Interactions

  • No known significant drug interactions
  • Diabetes medications — monitor blood sugar (may have mild effects)

Maximum Dose

Do not exceed: 1,000 mg/day was the highest dose in clinical trials

Full Caralluma Fimbriata Guide

References

  1. RCTKuriyan R, Raj T, Srinivas SK, et al. (2007). Effect of Caralluma fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women. Appetite. DOI PubMed
  2. Meta-analysisJayawardena R, Francis TV, Abhayaratna S, Ranasinghe P (2021). The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials.. BMC complementary medicine and therapies. DOI PubMed
  3. RCTRao A, Briskey D, Dos Reis C, Mallard AR (2021). The effect of an orally-dosed Caralluma Fimbriata extract on appetite control and body composition in overweight adults.. Scientific reports. DOI PubMed
  4. Kell G, Rao A, Katsikitis M (2019). A randomised placebo controlled clinical trial on the efficacy of Caralluma fimbriata supplement for reducing anxiety and stress in healthy adults over eight weeks.. Journal of affective disorders. DOI PubMed
  5. RCTGriggs JL, Su XQ, Mathai ML (2015). Caralluma Fimbriata Supplementation Improves the Appetite Behavior of Children and Adolescents with Prader-Willi Syndrome.. North American journal of medical sciences. DOI PubMed
  6. RCTAstell KJ, Mathai ML, McAinch AJ, Stathis CG, et al. (2013). A pilot study investigating the effect of Caralluma fimbriata extract on the risk factors of metabolic syndrome in overweight and obese subjects: a randomised controlled clinical trial.. Complementary therapies in medicine. DOI PubMed
  7. Astell KJ, Mathai ML, Su XQ (2013). Plant extracts with appetite suppressing properties for body weight control: a systematic review of double blind randomized controlled clinical trials.. Complementary therapies in medicine. DOI PubMed